Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Other Non-Current Liabilities (2023 - 2025)

Beta Bionics (BBNX) has disclosed Other Non-Current Liabilities for 3 consecutive years, with $1.5 million as the latest value for Q4 2025.

  • Quarterly Other Non-Current Liabilities fell 96.55% to $1.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.5 million through Dec 2025, down 96.55% year-over-year, with the annual reading at $1.5 million for FY2025, 96.55% down from the prior year.
  • Other Non-Current Liabilities hit $1.5 million in Q4 2025 for Beta Bionics, up from $1.2 million in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $44.9 million in Q4 2024 to a low of $400000.0 in Q1 2025.
  • Historically, Other Non-Current Liabilities has averaged $14.4 million across 3 years, with a median of $1.4 million in 2025.
  • Biggest five-year swings in Other Non-Current Liabilities: increased 19.5% in 2024 and later crashed 96.55% in 2025.
  • Year by year, Other Non-Current Liabilities stood at $37.6 million in 2023, then increased by 19.5% to $44.9 million in 2024, then plummeted by 96.55% to $1.5 million in 2025.
  • Business Quant data shows Other Non-Current Liabilities for BBNX at $1.5 million in Q4 2025, $1.2 million in Q3 2025, and $1.0 million in Q2 2025.